Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00323206 · ClinicalTrials.gov registry record · NA
Phase I Trial of Intratumoral pIL-12 Electroporation in Malignant Melanoma
A NA study, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Completed
- Registry status
- NA
- Development phase
- 24
- Enrollment target
NCT00323206 is a NA study that has completed, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 24 participants.
The verdict
NCT00323206, a NA study, has completed, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 24 participants
- Enrollment target
Study Summary
The purpose of this research study is to study a type of gene therapy treatment called plasmid electroporation. This type of treatment involves the injection of a gene into some melanoma tumors located near the surface of the skin, followed by a burst of electricity into the tumor to cause the tumor to take up the gene. This study is a Phase I study to determine the side effects and the correct dose of this type of treatment and also its effectiveness in treating melanoma. While the electroporation technique has been used in people, the combination of plasmid injection and electroporation is being tried in human beings for the first time.
Interventions
- BIOLOGICAL IL-12p DNA
- PROCEDURE Intratumoral Electroporation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2004-06 |
| Est. Completion | 2008-04 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00323206
The ClinicalTrials.gov registry entry for NCT00323206 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which IL-12p DNA is the first listed.
NCT00323206 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00323206 about?
NCT00323206 is a clinical study titled "Phase I Trial of Intratumoral pIL-12 Electroporation in Malignant Melanoma". The purpose of this research study is to study a type of gene therapy treatment called plasmid electroporation. This type of treatment involves the injection of a gene into some melanoma tumors located near the surface of the skin, followed by a burst of electricity into the tumor to cause the tumor...
What is the current status of trial NCT00323206?
This trial is currently completed. It is a NA study. The enrollment target is 24 participants. The study started on 2004-06. Estimated completion is 2008-04.
What interventions are being tested in trial NCT00323206?
The interventions under investigation include: IL-12p DNA (BIOLOGICAL), Intratumoral Electroporation (PROCEDURE).
Who is sponsoring clinical trial NCT00323206?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.